Intravenous magnesium sulfate to improve outcome after aneurysmal subarachnoid hemorrhage: interim report from a pilot study.
Magnesium sulfate (MgSO4) may be useful in preventing neurological injury after subarachnoid haemorrhage (SAH). In this randomized, double-blind study we evaluated the safety and efficacy of MgSO4 infusion to improve clinical outcome after aneurysmal SAH. With ethics committee approval and informed consents, 45 patients with SAH were randomly allocated to receive either MgSO4 80 mmol/day or saline infusion for 14 days. All patients also received intravenous nimodipine. Episodes of vasospasm were treated with hypertensive, hypervolemic therapy. Neurological status was assessed 3 months after haemorrhage using Barthel index and Glasgow outcome scale (GOS). Incidences of cardiac and pulmonary complications were also recorded. Data were compared between groups using Mann-Whitney or Fisher exact tests as appropriate. P < 0.05 was considered significant. Patient characteristics, severity of SAH and surgical treatment did not differ between groups. Although the number of episodes was not reduced, MgSO4 shortened the duration of vasospasm. Patients receiving MgSO4 tended to have fewer neurological deficits, better functional recovery and an improved score in GOS. However, none of these outcome variables reached statistical significance. The incidence of cardiac and pulmonary complications in the MgSO4 group (43%) was also similar to that in the saline group (59%), P = 0.14. MgSO4 infusion after aneurysmal SAH is well tolerated and may be useful in producing better outcome. A larger study is required to confirm the neuroprotective effect of MgSO4.